Search
Briacell Therapeutics Corp
BCTXAdd to Watchlist
4.010USD
-0.080-1.96%
Close 09-23 16:00（ET）
34.89MMarket Cap
LossP/E TTM
BCTX Analyst Recommendation Trends
In the current month, BCTX has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BCTX average Analyst price target in the last month is 40.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
BCTX Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, BCTX EPS is projected to reach -2.090 in FY2026Q4, following reported EPS of -0.988 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-3.28
-4.84
-2.74
-2.09
Actual
-4.35
-2.58
-0.99
--
Surprise
-32.66%
+46.75%
+63.94%
--
FAQs
What is Briacell Therapeutics Corp's expected revenue for the next quarter?
Briacell Therapeutics Corp's expected revenue is 2.10M.
How have Briacell Therapeutics CorpBCTX's recent earnings per share performed?
The market expectation was USD -0.99, while Briacell Therapeutics CorpBCTX's earnings per share (EPS) for the previous quarter was USD -2.58. EPS for the next quarter is expected at USD -2.09.
What is the analyst rating for Briacell Therapeutics Corp?
Based on the ratings of Briacell Therapeutics Corp's stock from 0 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.